Advitech's global roll out plan for its psoriasis nutraceutical
Dermylex is coming together, with definitive agreements in Canada
and France, interim financing, and new appointments as it moves
into the implementation phase.
Advitech is embroiled in discussions with potential partners to
bring its XP-828L product to market, targeting sufferers of mild to
moderate psoriasis and other inflammatory diseases.
A probiotic treatment almost reversed many of the symptoms of the
gut disease ulcerative colitis in a small trial, report researchers
at the University of Dundee in Scotland.